Five Prime Therapeutics is buying to Inhibrx's early-stage cancer R&D, signing a deal worth up to $452.5 million to get its hands on an immuno-oncology project.
Startup Clinical Ink said that it's in the midst of a pilot clinical study that incorporates medical device data that's collected through a smartphone app with biopharma Novartis and contract research organization PPD. The trial incorporates medical device connectivity that's provided by Clinical Ink and powered by Qualcomm's 2net Mobile Platform.
Researchers from Emory University have identified a set of long-lived antibody-producing cells in bone marrow. They function as a "catalog" of how an adult's immune system responded to measles or mumps viruses in childhood.
Contract drug developer Aptuit has bolstered its in-house production capabilities and can now churn out doses for Phase III trials, a move the company says was motivated by client demand.
In another demonstration of the big bets being made on reengineering T cells to attack cancer, Oxford, U.K.-based Immunocore has come up with a monster $320 million venture round designed to push the pipeline well past positive early stage data for its lead therapy.
AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.
CRO Frontage Laboratories has acquired a 45% stake in New Jersey's BDM Consulting, a biometrics-focused company looking to expand the market for its data services.
Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.
The National Science Foundation has coughed up almost $31 million since 2008 in an effort to develop what it has dubbed "smart implants" that address the underlying medical issue but then dissolve.
Bristol-Myers Squibb is teaming up with researchers at the Medical University of South Carolina to shed some light on the root causes of fibrotic disease, planning translational studies on a handful of ailments with hopes of spotlighting new treatments.